National Institute For Clinical Excellence (NICE) has launched a special scheme which will help people suffering from macular degeneration to avail Novartis AG's, pricey eye drug Lucentis through cost effective scheme.
This move, follows a draft plan in which the National Health Service will pay for a maximum of 14 injections of Lucentis per eye, with Novartis agreeing to pay if any more are needed.
Although NICE estimates that 14 shots of Lucentis would be more than enough to improve the vision.
Lucentis is an expensive drug, which cost more than 10,000 pounds for each eye treated. It is the most effective drug which helps in the formation of new blood vessels in the macular degenerated patients.